DGX250117C180000
- 0.37
- 0.000.00%
Quest Diagnostics Newsroom
Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $177
Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management
Mizuho Adjusts Price Target on Quest Diagnostics to $177 From $174, Keeps Outperform Rating
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Is Quest Diagnostics (NYSE:DGX) Using Too Much Debt?
Quest Diagnostics Deal Sends Mainz Higher
Express News | Mainz Biomed NV - Quest to Provide Lab Services for Mainz Biomed's Reconaasense Study
Express News | Mainz Biomed Forms Agreement With Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Quest Diagnostics Advances Environmental Stewardship With Renewable Energy Initiatives, Waste Reduction, and ISO 14001 Certifications in 2023
Health-care Sector Faces Mixed Prospects in 2025, Morgan Stanley Says
Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Morgan Stanley Upgrades Quest Diagnostics(DGX.US) to Buy Rating, Raises Target Price to $172
Morgan Stanley Upgrades Quest Diagnostics to Overweight From Equalweight, Adjusts Price Target to $172 From $145
Barclays Initiates Quest Diagnostics(DGX.US) With Hold Rating, Announces Target Price $168
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $182
Quest Diagnostics Coverage Assumed by Jefferies at Buy
Quest Diagnostics Analyst Ratings
Jefferies Initiates Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $185